Did You Know?

Editor’s Picks

Latest News

Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD

- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related...

BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference

CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

PRESS RELEASE                                                                         CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary...

error: Content is protected !!